Sumatriptan ameliorates renal injury induced by cisplatin in mice

Bazmandegan, Gholamreza and Amirteimoury, Morteza and Kaeidi, Ayat and Shamsizadeh, Ali and Khademalhosseini, Morteza and Nematollahi, Mohammad Hadi and hasanipoor, mahsa and Fatemi, Iman (2019) Sumatriptan ameliorates renal injury induced by cisplatin in mice. Iranian Journal of Basic Medical Sciences, 22 (5). pp. 563-567.

[img] Text
IJBMS_Volume 22_Issue 5_Pages 563-567.pdf

Download (772kB)
Official URL:


Objective(s): Cisplatin (Cis) is an anticancer compound, which is used for the treatment of various cancers. Sumatriptan (Suma) is a selective agonist of 5-hydroxytryptamine 1B/1D (5HT1B/1D) receptor, which is prescribed for the management of migraine. It is well-established that Suma has anti-in�ammatory and antioxidant properties. We have explored the protective effects of Suma in the mitigation of Cis-induced nephrotoxicity. Materials and Methods: The mice received a single IP injection of Cis (20 mg/kg) on the first day of the experiment. Suma treatment (0.1 and 0.3 mg/kg/day, IP) was started on day 1 and continued for 3 consecutive days. Results: Creatinine (Cr), blood urea nitrogen (BUN) and malondialdehyde (MDA) levels were elevated and glutathione peroxidase (GPx) as well as superoxide dismutase (SOD) activities were decreased in Cis-treated mice. Suma (more potently 0.3 mg/kg) reduced Cr, BUN and MDA levels and increased SOD and GPx levels. Suma also reduced the acute renal injury (tubular degeneration, tubular cells vacuolation, tubular necrosis and cast), which corresponded to kidney damage in Cis-treated mice. Conclusion: These findings demonstrate that Suma mitigates Cis-induced renal injury by inhibition of oxidative stress and enhancing the antioxidant enzymes activities.

Item Type: Article
Subjects: QV pharmacology
Divisions: Journals > Iranian J Basic Medical Sciences
Depositing User: ijbms ijbms
Date Deposited: 08 Apr 2019 05:37
Last Modified: 08 Apr 2019 05:37

Actions (login required)

View Item View Item